Pharmacological evidence for a role of liver X receptors in atheroprotection.
Kovanen
Petri T
PT
Wihuri Research Institute, Kalliolinnantie 4, 00140 Helsinki, Finland. petri.kovanen@wri.fi
Pentikäinen
Markku O
MO
D000818:Animals; D000924:Anticholesteremic Agents / Q000494:pharmacology / Q000627:therapeutic use; D001161:Arteriosclerosis / Q000378:metabolism / Q000517:prevention & control*; D001692:Biological Transport; D002784:Cholesterol / Q000378:metabolism; D004268:DNA-Binding Proteins; D006801:Humans; D006845:Hydrocarbons, Fluorinated; D008024:Ligands; D000071518:Liver X Receptors; D051379:Mice; D008954:Models, Biological; D057093:Orphan Nuclear Receptors; D018160:Receptors, Cytoplasmic and Nuclear / Q000502:physiology*; D013449:Sulfonamides; D014280:Triglycerides / Q000378:metabolism; D005466:Fluorocarbons; D000096926:Benzenesulfonamides
D000924:Anticholesteremic Agents; D002784:Cholesterol; D004268:DNA-Binding Proteins; D006845:Hydrocarbons, Fluorinated; D008024:Ligands; D000071518:Liver X Receptors; D057093:Orphan Nuclear Receptors; D018160:Receptors, Cytoplasmic and Nuclear; D013449:Sulfonamides; D014280:Triglycerides; C423915:T0901317; D005466:Fluorocarbons; D000096926:Benzenesulfonamides